Microbix Biosystems Inc. (MBX.TO)
| Previous Close | 0.3400 |
| Open | 0.3500 |
| Bid | 0.3450 x 0 |
| Ask | 0.3450 x 0 |
| Day's Range | 0.3450 - 0.3500 |
| 52 Week Range | 0.2300 - 0.4500 |
| Volume | |
| Avg. Volume | 49,429 |
| Market Cap | 47.163M |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 8.62 |
| EPS (TTM) | 0.0400 |
| Earnings Date | Aug 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Sept 02, 1999 |
| 1y Target Est | N/A |
Simply Wall St.Shareholders Shouldn’t Be Too Comfortable With Microbix Biosystems' (TSE:MBX) Strong Earnings
After announcing healthy earnings, Microbix Biosystems Inc.'s ( TSE:MBX ) stock rose over the last week. Despite the...
GlobeNewswireMicrobix Reports Continued Strong Results for Q3 Fiscal 2024
Revenues of $5.1 million and Net Income of $0.25 millionMISSISSAUGA, Ontario, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and first nine months of fiscal 2024 ended June 30, 2024 (“Q3” and “YTD”) with strong revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and resulting in mat
- GlobeNewswire
Microbix Schedules Release of Results for Q3 Fiscal 2024
Results Release and Webinar Discussion on Morning of August 14, 2024MISSISSAUGA, Ontario, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its third quarter of fiscal 2024 ended June 30, 2024 (“Q3 2024”) prior to the start of trading on August 14, 2024. Furthermore, at 10:00 AM ET on that day, M
